|
Targeting IL-6 pathway to treat high risk myelodysplastic syndromes
NU 2022-093
INVENTORS
Peng Ji*
Kehan Ren
Yang Mei
SHORT DESCRIPTION
A method of inhibiting progression of high-risk myelodysplastic syndrome (MDS) or low blast count acute myeloid leukemia (AML) using an inhibitor of IL6 signaling.
BACKGROUND
Approximately 20,000 people in the US are diagnosed with myelodysplastic syndrome (MDS) each year....
Published: 2/17/2026
|
Inventor(s):
Keywords(s): AML - Acute myeloid leukemia, Repurposed Drugs, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity
SHORT DESCRIPTION
A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists.
INVENTORS
Paul W Burridge*, PhD
Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine
* Principal Investigator
NU...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): Cancer Treatment, Cancer/Oncology, Cardiology and Cardiovascular disease, Chemotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Melanoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Gary Schiltz (PI)*
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer.
BACKGROUND
Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
The Use of Annexins in Preventing and Treating Muscle Membrane Injury
NU 2018-119
INVENTORS
Elizabeth McNally*
Alexis Demonbreun
SHORT DESCRIPTION
An annexin-based biological therapeutic that enhances the body's natural cell membrane repair process to reduce muscle cell death and preserve tissue function.
BACKGROUND
Cell membrane integrity is critical for survival, especially in tissues under constant mechanical...
Published: 12/9/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
New Therapeutic Approach for the Treatment of Acute Myeloid Leukemia
NU 2017-214
Inventors
Ali Shilatifard*
Zibo Zhao
Short Description
A new therapeutic approach for the treatment of acute myeloid leukemia using casein kinase inhibitors.
Background
Leukemia is a group of cancers that affects the bone marrow and results in the overproduction of dysfunctional white blood cells (WBCs). The mixed lineage leukemia...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel 2-Imidazolyl-Pyrimidine Inhibitors for Neurodegenerative Disease Therapeutics
NU 2014-101
INVENTORS
Richard Silverman*
Paramita Mukherjee
SHORT DESCRIPTION
This invention introduces novel 2-imidazolyl-pyrimidine scaffolds that inhibit neuronal nitric oxide synthase. It offers potential for drug development targeting Parkinson’s and other neurodegenerative diseases.
BACKGROUND
Neurodegenerative disorders such as...
Published: 12/3/2025
|
Inventor(s):
Keywords(s): Biomedical, Materials, Neurodegenerative disease, Neurologic disease, Neurology, Small molecule, Therapeutics
Category(s): Physical Sciences > Materials and Industrial Processes
|
|
Arylazanylpyrazolone Inhibition of Mutant SOD1 Mediated Cytotoxicity and Application to the Treatment of ALS
✅ Feedback form for Tech ID 2012-178
PROPOSED TITLE: Arylazanylpyrazolone Inhibition of Mutant SOD1 Cytotoxicity for ALS Treatment
NU 2012-178
INVENTORS
Richard Silverman*
Yinan Zhang
SHORT DESCRIPTION
Compounds based on arylazanylpyrazolone derivatives inhibit mutant SOD1-mediated cytotoxicity, offering a promising approach for ALS treatment.
BACKGROUND
Amyotrophic...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
2-(Pyridin-3-yl)quinazoline compounds as glucocerebrosidase modulators
✅ Feedback form for Tech ID 2015-064
PROPOSED TITLE: 2-(Pyridin-3-yl) quinazoline Compounds as Glucocerebrosidase Modulators
NU 2015-064
INVENTORS
Richard Silverman*
Dimitri Krainc
Jianbin Zheng
SHORT DESCRIPTION
Novel substituted quinazoline compounds that modulate glucocerebrosidase activity, offering a promising therapeutic approach for...
Published: 11/18/2025
|
Inventor(s):
Keywords(s): Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Research tool, Therapeutics
Category(s): Life Sciences > Therapeutics
|